SCHEMBL6854050

SCHEMBL6854050

OCc1oc2ccccc2c1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 5/20 0.40
PTPN1 P18031 4/20 0.40
MAPT P10636 3/20 0.40
HSD17B10 Q99714 3/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP3A4 P08684 3/20 0.40
CYP2C9 P11712 3/20 0.40
HPGD P15428 2/20 0.40
SLC22A12 Q96S37 2/20 0.40
EYA3 Q99504 2/20 0.40
MEN1 O00255 2/20 0.40
ABCB11 O95342 2/20 0.40
LMNA P02545 2/20 0.40
CYP1A2 P05177 2/20 0.40
TSHR P16473 2/20 0.40
MAPK1 P28482 2/20 0.40
KMT2A Q03164 2/20 0.40
PDE4D Q08499 2/20 0.40
TTR P02766 2/20 0.40
CHRM2 P08172 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3380979 0.82 ALDH1A1 (0.40) CYP2C19PTPN1MAPTHSD17B10ALDH1A1
SCHEMBL2775764 0.80 CYP2C19 (0.50) CYP2C19PTPN1MAPTHSD17B10ALDH1A1
SCHEMBL12499206 0.77 NPSR1 (0.40) CYP2C19MAPTHSD17B10ALDH1A1CYP3A4
SCHEMBL2256874 0.76 KDM4E (0.46) CYP2C19PTPN1MAPTHSD17B10ALDH1A1
SCHEMBL4250447 0.76 CA12 (0.39) CYP2C19PTPN1MAPTHSD17B10ALDH1A1
SCHEMBL28018757 0.74 PTPN1 (0.55) PTPN1EYA3TTR
SCHEMBL11901872 0.73 MAPT (0.60) PTPN1MAPTCYP3A4MEN1LMNA
SCHEMBL13348986 0.73 ABCB1 (0.46) CYP2C19PTPN1MAPTHSD17B10ALDH1A1
SCHEMBL595885 0.72 ALDH1A1 (0.41) CYP2C19MAPTHSD17B10ALDH1A1CYP3A4
SCHEMBL2483045 0.72 MAOA (0.53) CYP2C19MAPTHSD17B10ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6780859-B2 FOR THERAPY OF DIABETES, OBESITY, IMPAIRED GLUCOSE TOLERANCE, GASTROINTESTINAL DISORDERS, HYPERTRIGLYCERIDEMIA, HYPERCHOLESTEOLEMIA, ATHEROSCLEROTIC DISORDERS, OR CARDIOVASCULAR DISORDERS BAYER PHARMACEUTICALS CORPORATION 2004-08-24 US disclosed